Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous ...

Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous ...

The leading Metastatic Merkel Cell Carcinoma Companies such as Incyte Corporation, Merck, Pfizer, Millennium Pharmaceuticals ...

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...

Anal cancer is relatively uncommon, accounting for approximately 2.5% of all gastrointestinal cancers. Nonetheless, its ...

A common and unsightly skin cancer that can turn deadly has been undetectable for more than a year in a patient treated with ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

The global, randomized IDeate-Esophageal01 study will evaluate ifinatamab deruxtecan, a B7-H3–targeted antibody-drug ...

Bcl6 regulates the lineage stability and suppressive function of Treg cells in head and neck squamous cell carcinoma ...

Patients with CSCC who had lymphovascular invasion had a greater incidence of metastasis and disease-specific death than those without.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...